The Indiana Biosciences Research Institute has announced Chief Executive Officer and Chief Scientific and Innovation Officer Rainer Fischer has stepped down from both roles. The institute says Fischer, who came to Indianapolis in 2017, will remain as a senior executive for innovation and discovery. The IBRI did not provide a reason for Fischer’s decision to step down.
In his new role, Fischer will work to attract new partners for sponsored and contract research, as well as new donors and grant-makers. The institute says he will also continue to build out research labs at Purdue University as part of the presidential fellowship and research professorship he received from the university last year.
"My first love is science, particularly research and development, and facilitating the scientific and funding partnerships necessary to yield meaningful and major discoveries," Fischer said in a news release. "In this more focused scientific and discovery role, I will be even more effective in helping to grow the IBRI’s partnerships, funding and talent.”
Fischer was named the CSIO of the institute in October 2016 and began the role the following April. In October 2017, he was named CEO following the departure of the institute’s founding CEO, David Broecker.
"We’re grateful for Dr. Fischer’s service in these dual roles, which included broadening the IBRI’s diabetes research and expanding our focus to include the newly created Pharmaceutical Biotechnology Center," said Dan Evans, chairman of the board for the IBRI. "We have initiated a search to find a CEO who will support Dr. Fischer and the entire IBRI team with the leadership, vision and capabilities necessary to maintain our growth. During this time, we expect to conduct business as usual with no disruptions in research or operations."
The IBRI did not provide a time frame for choosing Fischer’s successor.